Shellback Capital LP Purchases New Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

Shellback Capital LP acquired a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 161,688 shares of the company's stock, valued at approximately $1,353,000. Shellback Capital LP owned 0.58% of Delcath Systems at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Cubist Systematic Strategies LLC bought a new stake in Delcath Systems in the second quarter valued at $370,000. Levin Capital Strategies L.P. grew its position in Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company's stock valued at $262,000 after acquiring an additional 5,969 shares during the period. Renaissance Technologies LLC bought a new stake in Delcath Systems in the second quarter valued at $694,000. Marshall Wace LLP grew its position in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company's stock valued at $776,000 after acquiring an additional 6,066 shares during the period. Finally, Legato Capital Management LLC bought a new stake in Delcath Systems in the second quarter valued at $966,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Price Performance

Shares of Delcath Systems stock traded up $0.26 during trading hours on Friday, hitting $9.13. The company's stock had a trading volume of 163,929 shares, compared to its average volume of 254,813. Delcath Systems, Inc. has a 12 month low of $2.25 and a 12 month high of $11.74. The stock has a 50 day moving average of $8.90 and a 200 day moving average of $7.20. The company has a market capitalization of $253.72 million, a PE ratio of -3.40 and a beta of 0.78.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The business had revenue of $7.77 million during the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the company earned ($0.58) earnings per share. Equities analysts expect that Delcath Systems, Inc. will post -1.67 EPS for the current year.

Wall Street Analysts Forecast Growth

DCTH has been the topic of a number of analyst reports. Craig Hallum initiated coverage on Delcath Systems in a research report on Friday, June 28th. They issued a "buy" rating and a $18.00 price target on the stock. Stephens reaffirmed an "overweight" rating and set a $25.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. Finally, StockNews.com raised Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.